13D Filing: OrbiMed Advisors and Arsanis Inc (ASNS)

Page 3 of 13

Page 3 of 13 – SEC Filing

CUSIP No. 042873109
1
NAME OF REPORTING PERSON

OrbiMed Capital GP IV LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)
3
SEC USE ONLY
4
SOURCE OF FUNDS

N/A
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
1,868,966
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
1,868,966
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,868,966
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13.07%*
14
TYPE OF REPORTING PERSON (See Instructions)

OO
*
This percentage is calculated based upon 14,294,383 shares of Common Stock (as defined below) of the Issuer outstanding, as set forth in the Issuer’s Prospectus filed with the Securities and Exchange Commission on November 17, 2017 pursuant to Rule 424(b)(1) of the Securities Act of 1933, as amended, and after giving effect to the additional 600,000 shares of Common Stock issued and sold by the Issuer to the underwriters pursuant to the underwriters’ option.

Follow X4 Pharmaceuticals Inc (NASDAQ:XFOR)

Page 3 of 13